Current Surgical Indications for Non-Small-Cell Lung Cancer

Authors

Nathaniel Deboever
Kyle G Mitchell
Hope A Feldman
Tina Cascone
Boris Sepesi

Publication Date

2-28-2022

Journal

Cancers

Abstract

With recent strides made within the field of thoracic oncology, the management of NSCLC is evolving rapidly. Careful patient selection and timing of multi-modality therapy to permit the optimization of therapeutic benefit must be pursued. While chemotherapy and radiotherapy continue to have a role in the management of lung cancer, surgical therapy remains an essential component of lung cancer treatment in early, locally and regionally advanced, as well as in selected, cases of metastatic disease. Recent and most impactful advances in the treatment of lung cancer relate to the advent of immunotherapy and targeted therapy, molecular profiling, and predictive biomarker discovery. Many of these systemic therapies are a part of the standard of care in metastatic NSCLC, and their indications are expanding towards surgically operable lung cancer to improve survival outcomes. Numerous completed and ongoing clinical trials in the surgically operable NSCLC speak to the interest and importance of the multi-modality therapy even in earlier stages of NSCLC. In this review, we focus on the current standard of care indications for surgical therapy in stage I-IV NSCLC as well as on the anticipated future direction of multi-disciplinary lung cancer therapy.

Keywords

non-small-cell lung cancer, lobectomy, pneumonectomy, sublobar resection, surgery, enhanced recovery pathways, thoracoscopy, video-assisted thoracoscopic surgery, robotic-assisted thoracic surgery

DOI

10.3390/cancers14051263

PMID

35267572

PMCID

PMC8909782

PubMedCentral® Posted Date

2-28-2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes